UNICYCIVE THERAPEUTICS, INC. Investing Cash Flow
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Investing Cash Flow of -$5.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$23.00K.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$5.16M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$12.07M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$2.00K.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$12.10M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$72.00K.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$12.00K.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$2.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.18M 10-Q · filed 2026-08-12 | -$17.25M derived: sum of 3 quarters · filed 2026-08-12 | -$17.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$5.16M 10-Q · filed 2026-05-12 | -$17.23M derived: sum of 2 quarters · filed 2026-05-12 | -$17.23M derived: sum of 3 quarters · filed 2026-05-12 | -$17.23M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$12.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$12.07M derived: sum of 2 quarters · filed 2026-03-30 | -$12.08M derived: sum of 3 quarters · filed 2026-08-12 | -$12.10M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$8.00K derived: sum of 2 quarters · filed 2026-08-12 | -$24.00K 10-Q · filed 2025-11-12 | -$46.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$22.00K 10-Q · filed 2026-08-12 | -$44.00K derived: sum of 3 quarters · filed 2026-08-12 | -$68.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$16.00K 10-Q · filed 2026-05-12 | -$38.00K derived: sum of 2 quarters · filed 2026-05-12 | -$62.00K derived: sum of 3 quarters · filed 2026-05-12 | -$82.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$46.00K derived: sum of 2 quarters · filed 2026-03-30 | -$66.00K derived: sum of 3 quarters · filed 2026-03-30 | -$72.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$44.00K derived: sum of 2 quarters · filed 2025-11-12 | -$50.00K 10-Q · filed 2025-11-12 | -$50.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$26.00K 10-Q · filed 2025-08-14 | -$26.00K derived: sum of 3 quarters · filed 2025-08-14 | -$26.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$6.00K 10-Q · filed 2025-05-14 | -$6.00K derived: sum of 2 quarters · filed 2025-05-14 | -$6.00K derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | -$12.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$12.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$12.00K 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | -$2.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | -$2.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$2.00K 10-Q · filed 2023-05-16 | |||
| 2021-12-31 | -$29.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |